載入中
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
收盤時
US$0.2167
−US$0.0212 · -8.91%
盤後
US$0.2171
+US$0.0004 · +0.18%
10月13日 下午5:25 ET
盤中時間採用ET。市場資料可能有所延遲。
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
日內區間
目前US$0.2167
52週區間
目前US$0.2167
盤中時間採用ET。市場資料可能有所延遲。
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
日內區間
目前US$0.2167
52週區間
目前US$0.2167
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1032.5萬 USD | 281.6萬 USD | 2104.9萬 USD | 1353.5萬 USD | 1014.1萬 USD |
| 銷貨成本 | 286.6萬 USD | — | — | — | — |
| 毛利 | 745.9萬 USD | 281.6萬 USD | 2104.9萬 USD | 1353.5萬 USD | 1014.1萬 USD |
| 研究與開發 | 1.14億 USD | 1.07億 USD | 8815.3萬 USD | 5981.9萬 USD | 4495.4萬 USD |
| 銷售、一般及管理費用 | 3198.8萬 USD | 2955.9萬 USD | 2549.2萬 USD | 2035.2萬 USD | 1382.8萬 USD |
| 營業費用 | 1.43億 USD | 1.38億 USD | 1.15億 USD | 8017.1萬 USD | 5878.2萬 USD |
| 利息收入 | 881.6萬 USD | 1206.5萬 USD | 799.9萬 USD | 159.1萬 USD | 1.6萬 USD |
| 利息支出 | 276.9萬 USD | 365.3萬 USD | 375.9萬 USD | 117.6萬 USD | — |
| 折舊和攤銷 | 286.6萬 USD | 410.8萬 USD | 536.1萬 USD | 513.7萬 USD | 332.8萬 USD |
| 營業利益 | −1.36億 USD | −1.35億 USD | −9345.8萬 USD | −6663.6萬 USD | −4864.1萬 USD |
| 淨利 | −1.3億 USD | −1.27億 USD | −8921.8萬 USD | −6622.1萬 USD | −4862.5萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$1.00
上漲空間 361.47%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI134.49萬0.00%2.3兆 USD0.03%US$381.32-0.07%
Vanguard Extended Market ETFVXF48.58萬0.00%954億 USD0.05%US$232.54-0.42%
iShares Micro-Cap ETFIWC3.78萬0.00%13.17億 USD0.60%US$179.6-1.13%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM2萬0.01%1.16億 USD0.73%US$15.6501-1.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
